Tyler A. Lesh

Tyler A. Lesh

Auto-generated profile, based on publicly available information

Tyler A. Lesh

Department of Psychiatry and Behavioral Sciences, University of California, Davis, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2010 in Neuropsychopharmacology
Verified
Journal Article
Closed access
TLTyler A Lesh
Tyler A Lesh
TNTara Niendam
Tara Niendam
MMMichael J Minzenberg
Michael J Minzenberg
CCCameron S Carter
Cameron S Carter

1 January 2013 in NeuroImage: Clinical
Verified
Journal Article
Open access
TLTyler A. Lesh
Tyler A. Lesh
AWAndrew J. Westphal
Andrew J. Westphal
TNTara Niendam
Tara Niendam
JYJong H. Yoon
Jong H. Yoon
MMMichael J. Minzenberg
Michael J. Minzenberg
CCCameron S. Carter
Cameron S. Carter
Cognitive control deficits have been consistently documented in patients with schizophrenia. Recent work in cognitive neuroscience has hypothesized a distinction between two theoretically separable modes of cognitive control-reactive and proactive. However, it remains unclear the extent to which these processes are uniquely associated with dysfunctional neural recruitment in individuals with schizophrenia. This functional magnetic resonance imaging (fMRI) study utilized the color word Stroop task and AX Continuous Performance Task (AX-CPT) to tap reactive and proactive control processes, respectively, in a sample of 54 healthy controls and 43 patients with first episode schizophrenia. Healthy controls demonstrated robust dorsolateral prefrontal, anterior cingulate, and parietal cortex activity on both tasks. In contrast, patients with schizophrenia did not show any significant activation during proactive control, while showing activation similar to control subjects during reactive control. Critically, an interaction analysis showed that the degree to which prefrontal activity was reduced in patients versus controls depended on the type of control process engaged. Controls showed increased dorsolateral prefrontal cortex (DLPFC) and parietal activity in the proactive compared to the reactive control task, whereas patients with schizophrenia did not demonstrate this increase. Additionally, patients' DLPFC activity and performance during proactive control was associated with disorganization symptoms, while no reactive control measures showed this association. Proactive control processes and concomitant dysfunctional recruitment of DLPFC represent robust features of schizophrenia that are also directly associated with symptoms of disorganization.

1 March 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
TLTyler A. Lesh
Tyler A. Lesh
CTCostin Tanase
Costin Tanase
BGBenjamin R. Geib
Benjamin R. Geib
TNTara Niendam
Tara Niendam
JYJong H. Yoon
Jong H. Yoon
CCCameron S. Carter
Cameron S. Carter
In the 40 years since the classic study by Johnstone and colleagues,1 schizophrenia has been understood as a disorder characterized by alterations in brain structure, with the most robust findings including ventricular enlargement and reductions in overall gray matter volume.2 Studies of cortical thickness and surface area have also revealed consistent patterns of frontotemporal thinning in patients with chronic3-5 and first-episode6-10 schizophrenia. In recent years, accumulating evidence suggests that antipsychotics may contribute to observed structural brain changes, including the cortical and subcortical structures.11,12 Some studies suggest that typical antipsychotics may be associated with more dramatic structural changes (ie, larger reductions in gray matter volume, increased caudate and putamen volume) than atypical agents,5,13 whereas others fail to find a structural relationship with specific medications.3,14 In addition, studies of brain volume, cortical thickness, and surface area in antipsychotic-naive8,15 and prodromal16 individuals reveal that structural abnormalities are present before the initiation of antipsychotic therapy. These findings suggest that antipsychotics may contribute to findings of gray matter reduction in schizophrenia, but measurable changes are also caused by the illness itself.

26 May 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
TLTyler A. Lesh
Tyler A. Lesh
MCMilo Careaga
Milo Careaga
DRDestanie Rose
Destanie Rose
AMA. Kimberley McAllister
A. Kimberley McAllister
JWJudy Van de Water
Judy Van de Water
PAPaul Ashwood
Paul Ashwood
Over the past 30 years, evidence has been accumulating for an immunological component to schizophrenia etiology, including genetic links to the major histocompatibility complex, microglia activation, and dysregulated cytokine profiles. However, the degree of similarity in cytokine profiles for schizophrenia and bipolar disorder, as well as the relationship between cytokine levels and brain structure, is less well understood. To address this, we recruited 69 first-episode schizophrenia-spectrum patients, 16 first-episode bipolar patients with psychotic features, and 53 healthy controls, from the UC Davis EDAPT clinic. Blood plasma was collected and analyzed for all participants with a subset of participants that also underwent structural MRI on a 1.5T GE scanner. Plasma levels of interleukin (IL)-1β, IL-2, IL-6, and interferon (IFN)-γ were elevated in schizophrenia patients compared to those in controls. Patients with bipolar disorder had elevated plasma IL-10 levels compared to controls, and the two patient groups did not differ significantly on any immunological measure. Percent whole-brain gray matter was inversely correlated with IFN-γ and IL-12 levels in patients with schizophrenia, with a trend relationship between IFN-γ and IL-12 and prefrontal cortical thickness. Furthermore, psychotic symptoms were positively related to IL-1β levels in individuals with schizophrenia. These data suggest a partially overlapping pattern of elevated blood cytokine levels in patients with first-episode schizophrenia and bipolar disorder with psychotic features. Furthermore, our findings suggest that elevated pro-inflammatory cytokines may be particularly involved in schizophrenia etiology, given evidence of cytokine-related decreases in total gray matter.

1 September 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
JRJ. Daniel Ragland
J. Daniel Ragland
CRCharan Ranganath
Charan Ranganath
MHMichael P. Harms
Michael P. Harms
DBDeanna M. Barch
Deanna M. Barch
JGJames M. Gold
James M. Gold
CCCameron S. Carter
Cameron S. Carter
Long-term memory for episodic events can be facilitated by focusing on distinctive features of individual items (ie, item-specific encoding) or examining relationships between multiple items (ie, relational encoding). These encoding processes are of scientific interest because they are mediated by distinct subregions in prefrontal cortex (PFC)1,2 and they differentially affect representations formed in medial temporal lobe (MTL)3-5 subregions. Given evidence6-10 that schizophrenia may disproportionately impair relational memory, an essential next step is to develop an efficient task to differentiate between relational and item-specific processing in individuals with psychiatric disorders.

1 January 2018 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
DJDaniel C. Javitt
Daniel C. Javitt
CCCameron S. Carter
Cameron S. Carter
JKJohn H. Krystal
John H. Krystal
JKJoshua T. Kantrowitz
Joshua T. Kantrowitz
RGRagy R. Girgis
Ragy R. Girgis
JLJeffrey A. Lieberman
Jeffrey A. Lieberman
Quiz Ref ID All currently approved treatments for schizophrenia, including both typical and atypical antipsychotics, function primarily by blocking dopamine D2 receptors.1,2 Nevertheless, these compounds are fully effective for only a minority of individuals with schizophrenia, indicating the need for alternative treatment approaches.3,4 Recent theories implicate dysfunction of brain glutamatergic systems in general and of neurotransmission mediated by N-methyl-D-aspartate-type glutamate receptors (NMDAR) in particular. This latter theory is based on the ability of phencyclidine, ketamine, MK-801 (dizocilpine), or other NMDAR antagonists to induce clinical symptoms and neurocognitive dysfunction closely resembling those of schizophrenia.5-7 In rodent studies, effects of NMDAR antagonists such as ketamine8,9 are mediated, at least in part, by stimulation of presynaptic glutamate release in frontal brain regions and are reversed by compounds acting either to enhance postsynaptic NMDAR function or to diminish presynaptic glutamate release, which either reverse the primary deficit in NMDAR dysfunction or block the NMDAR antagonist–induced increase in presynaptic glutamate release.9-11